Is it time to reassess 3M (MMM) after PFAS settlement and restructuring efforts?

Yahoo!Finance | May 1, 2026

Read the full article (Yahoo!Finance)

"Approach 1: Pfizer Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting its future cash flows and discounting them back to a present value. It focuses on the cash the company may generate for shareholders rather than short term market moves.

For Pfizer, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about US$8.5b. Analyst inputs and subsequent extrapolations suggest free cash flow projections in the US$16b to US$20b range over the coming years, with the 2030 estimate at about US$16.4b and a set of discounted projections running through 2035.

Pulling these cash flows together, the DCF model points to an estimated intrinsic value of US$64.92 per share. Against the recent share price of US$26.70, the model output indicates an intrinsic discount of about 58.9% on this cash flow view."